AffiliationDivision of Cancer Sciences, University of Manchester, Manchester
MetadataShow full item record
AbstractBiliary tract cancers, including intrahepatic, perihilar, and distal cholangiocarcinoma as well as gallbladder cancer, are low-incidence malignancies in most high-income countries, but represent a major health problem in endemic areas; moreover, the incidence of intrahepatic cholangiocarcinoma is rising globally. Surgery is the cornerstone of cure; the optimal approach depends on the anatomical site of the primary tumour and the best outcomes are achieved through management by specialist multidisciplinary teams. Unfortunately, most patients present with locally advanced or metastatic disease. Most studies in advanced disease have pooled the various subtypes of biliary tract cancer by necessity to achieve adequate sample sizes; however, differences in epidemiology, clinical presentation, natural history, surgical therapy, response to treatment, and prognosis have long been recognised. Additionally, the identification of distinct patient subgroups harbouring unique molecular alterations with corresponding targeted therapies (such as isocitrate dehydrogenase-1 mutations and fibroblast growth factor receptor-2 fusions in intrahepatic cholangiocarcinoma, among others) is changing the treatment paradigm. In this Seminar we present an update of the causes, diagnosis, molecular classification, and treatment of biliary tract cancer.
CitationValle JW, Kelley RK, Nervi B, Oh DY, Zhu AX. Biliary tract cancer. Lancet. 2021;397(10272):428-44.
- Molecular characteristics of biliary tract cancer.
- Authors: Sohal DP, Shrotriya S, Abazeed M, Cruise M, Khorana A
- Issue date: 2016 Nov
- Genomic Profiling of Biliary Tract Cancers and Implications for Clinical Practice.
- Authors: Jain A, Kwong LN, Javle M
- Issue date: 2016 Nov
- Molecular targeted therapies: Ready for "prime time" in biliary tract cancer.
- Authors: Lamarca A, Barriuso J, McNamara MG, Valle JW
- Issue date: 2020 Jul
- Therapeutic relevance of targeted sequencing in management of patients with advanced biliary tract cancer: DNA damage repair gene mutations as a predictive biomarker.
- Authors: Chae H, Kim D, Yoo C, Kim KP, Jeong JH, Chang HM, Lee SS, Park DH, Song TJ, Hwang S, Kim KH, Song GW, Ahn CS, Lee JH, Hwang DW, Kim SC, Jang SJ, Hong SM, Kim TW, Ryoo BY
- Issue date: 2019 Oct
- Imaging of malignancies of the biliary tract- an update.
- Authors: Hennedige TP, Neo WT, Venkatesh SK
- Issue date: 2014 Apr 22